Searched for
WUXI BIOLOGICS
CDMO and weight loss drugs poised for major growth in pharma sector: Ravi DharamshiAs companies hire more, as jobs get generated, everybody wants to have a better place to live, better lifestyle and this is a big kind of a...- Chinese businesses hoping to expand in the US and bring jobs face uncertainty and suspicionU.S. wariness of China, coupled with Beijing's desire to protect its technological competitiveness, threatens to rupture ties between the w...
- Doing nothing could be the riskiest thing of allThe cost of “doing nothing” in markets can indeed be substantial, but that pales in comparison to the cost of complacency when the margin o...
- Investors are unwinding the 'buy India, sell China' stocks tradeMore than 90% of emerging market funds are adding back their positions in mainland Chinese shares, which were underweight, while also diali...
- Syngene can put on muscle as global pharma companies increase R&D spendingSyngene is a fully integrated CRAMS company and Biocon has around 70% stake in it. Syngene also has a wholly-owned subsidiary in the US.
- Chinese blue-chip index falls as U.S. sanction risks weighAt the close, the Shanghai Composite index was up 0.67% at 3,452.63. The blue-chip CSI300 index fell 0.55%, recovering after it hit a 19-mo...
- China's Brii says its COVID-19 antibody cocktail retains activity against OmicronTest details for the dual-antibody treatment, which last week became the first approved COVID-19 antibody cocktail in China, would not be a...
- Hong Kong shares end lower, dragged by property, financials and techChina Evergrande Group plunged nearly 12% to its lowest in more than six years, after it warned of a risk of cross-default as real estate s...
- Time to spread bets overseasAs equity valuations turn expensive amid the recordbreaking rally, financial planners are telling investors to diversify their stock portfo...
- Pfizer to halt biosimilar output in China, sell assets to WuXi BiologicsThe pharmaceutical industry increasingly relies for its profits on costly biologic drugs, made from living organisms that are tougher and m...
- Bet on consumption theme as the economy opens up: Radhika Gupta, Edelweiss AMC“A combination of improved macros and a weaker dollar generally bodes well for emerging markets flows.”
- Alibaba, Xiaomi to join Hong Kong's Hang Seng IndexThe change announced by the Hang Seng Indexes Company on Friday was made possible after the 50-year-old benchmark's publisher changed the r...
- Syngene plans to scale up for biologicsSyngene, an arm of Biocon, is expanding its capital investment as it waits to complete a 40-acre, $100-million research facility in Mangalo...
- Biocon sets Syngene IPO price band at Rs 240-250Biocon plans to raise Rs 550 crore by diluting 11% stake in Syngene through the Initial Public Offer. The proceeds will mostly go into fund...
- Market needs to look at Biocon as a bellwether stock: Kiran Mazumdar Shaw"The biggest problem is that investors do not want us to spend on R&D and R&D is a very integral part of our business."
Load More
